Drug Trial Radar · NCT00350636
A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo
Last checked: Nov 20, 2026Latest source record: May 10, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
789
Actual
Start
Jun 2006
Primary completion
May 2007
Study completion May 2007
Sponsor
- Lead sponsor
- Watson PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jul 11, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.
Conditions
- Overactive Bladder
Interventions
Oxybutynin topical gelDrug
1 application daily to skin for 12 weeks
Placebo topical gelOther
1 application daily to skin for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Baseline Average Number of Daily Incontinence EpisodesTime frame: Baseline
- Change From Baseline in Average Daily Number of Incontinence EpisodesTime frame: Baseline to Week 12
Locations
63 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Homewood, Alabama
Site not named
Mobile, Alabama
Site not named
Montgomery, Alabama
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Little Rock, Arkansas
Site not named
Anaheim, California
Site not named
Buena Park, California
Site not named
Laguna Woods, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
Torrance, California
Site not named
Denver, Colorado
Site not named
Waterbury, Connecticut
Site not named
Aventura, Florida
Site not named
Clearwater, Florida
Site not named
DeLand, Florida
Site not named
Leesburg, Florida
Site not named
Ocala, Florida
Site not named
Plantation, Florida
Site not named
Tallahassee, Florida
Site not named
West Palm Beach, Florida
Site not named
Alpharetta, Georgia
Site not named
Atlanta, Georgia
Site not named
Belville, Illinois
Site not named
Chicago, Illinois
Site not named
Melrose Park, Illinois
Site not named
Evansville, Indiana
Site not named
South Bend, Indiana
Site not named
Shreveport, Louisiana
Site not named
Watertown, Massachusetts
Site not named
Saginaw, Michigan
Site not named
Saint Joseph, Michigan
Site not named
Omaha, Nebraska
Site not named
Las Vegas, Nevada
Site not named
Albuquerque, New Mexico
Site not named
Albany, New York
Site not named
Garden City, New York
Site not named
New York, New York
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.